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COST-EFFECTIVENESS OF CETUXIMAB COMBINED WITH 
RADIOTHERAPY FOR PATIENTS WITH LOCALLY ADVANCED HEAD 
AND NECK CANCER IN TAIWAN
Chan AL1, Leung HW2, Lin SJ3
1Chi Mei Medical Center, Tainan, Taiwan, 2Taipei Medical University-Shuang Ho Hospital,, 
Jhonghe City, Taiwan, 3Kaohsiung Medical University, Kaohsiung , Taiwan
OBJECTIVES: The aim of this study was conducted to estimate the cost-effectiveness 
of cetuximab combined with radiotherapy compared to radiotherapy alone in patients 
with locally advanced squamous cell carcinoma of head and neck. METHODS: A 
decision-tree analysis was used to compare cetuximab combined with radiotherapy 
and radiotherapy alone in the treatment of patients with locally advanced squamous 
cell carcinoma of head and neck from the perspective of the Bureau of National Health 
Insurance(BNHI) in Taiwan. The model was based on individual patient data 
extracted from an international phase III trial. The direct medical costs of care were 
based on the reimbursement of Bureau of National Health Insurance in Taiwan. 
One-way sensitivity analyses were performed with varying the costs and clinical 
parameters. RESULTS: The incremental cost per quality-adjusted life-year for patients 
receiving radiotherapy in combination with cetuximab compared to radiotherapy 
alone was in the range of $70,469/yr to $542,334/yr in the base-case analysis. Sensitiv-
ity analysis showed the robust results. CONCLUSIONS: This study demonstrated the 
addition of cetuximab to high-dose radiotherapy regimen is likely to be cost-effective 
in consideration of higher locoregional control rate to be achieved compared to 
radiotherapy alone for locally advanced head and neck cancer in Taiwan.
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THE POTENTIAL IMPACT OF USING CHANGES IN SERUM HER2  
LEVELS TO INITIATE THERAPY CHANGE IN HER2+ METASTATIC 
BREAST CANCER
Noy K1, Dejori M1, Ghosh P2, Suhail AM3, Leitzel K4, Lipton A4, Carney W5, 
Wittenberg G1
1Siemens Corporate Research, Princeton, NJ, USA, 2University of Erlangen-Nuremberg, 
Erlangen, Germany, 3VA Medical Center, Lebanon, PA, USA, 4Pennsylvania State University 
College of Medicine, Hershey, PA, USA, 5Siemens Healthcare Diagnostics, Cambridge, MD, 
USA
OBJECTIVES: The goal of personalized medicine is to identify the right treatment for 
the right patient at the right time. Prior to treating metastatic breast cancer (MBC) 
patients with Herceptin, tumors are tested for overexpression of HER2. Still for many 
HER2 + patients (treated with herceptin), disease progression continues. It has previ-
ously been shown that for MBC changes in patients’ serum HER-2 levels during 
treatment is predictive of their eventual response to therapy. Through modeling and 
simulation we examine the potential impact of ceasing Herceptin therapy prior to the 
end of the planned treatment cycle for patients whose serum HER-2 levels predict an 
eventual lack of therapeutic response. METHODS: Markov Cycle Tree models were 
constructed to simulate disease progression and therapy for MBC patients using our 
custom simulation software, ProFound. The progression of disease was dependent on 
the patient’s current therapy: Herceptin, Tykerb, or Paclitaxel, and model parameters 
were based on meta-analysis of clinical trials. Patients are stratiﬁed into three sets: 
Serum HER-2 Increasing (>20%), Not Changing, and Decreasing (>20%). We com-
pared the following alternative treatment strategies: Paclitaxel, Herceptin, and initial 
Herceptin with change in therapy after 1 month based on changes in serum HER2. 
Patients removed from Herceptin either simply discontinued therapy or were switched 
to Tykerb. RESULTS: Compared with continued treatment with Herceptin, moving 
patients with >20% increase in Serum HER-2 to Tykerb resulted in an additional one 
life-month gained. All other strategies performed worse than continued Herceptin 
therapy, including moving patients whose Serum HER2 levels are not decreasing to 
Tykerb. This highlights the importance of identifying the right subset of patients who 
will beneﬁt from a change in therapy. CONCLUSIONS: A biomarker that can predict 
therapy failure prior to the end of treatment as part of the treatment decision-making 
process may extend the lives of patients.
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COST-EFFECTIVENESS OF LENOGRASTIM NEUTROPENIA DURATION 
IN ADULTS RECEIVING CHEMOTHERAPY FOR LEUKEMIA
Rutkowski J1, Derylo L1, Fedyna M1, Plisko R1, Lis J2, Wladysiuk M1
1HTA Consulting, Krakow, Poland, 2Sanoﬁ-Aventis Sp. z o.o., Warsaw, Poland
OBJECTIVES: The aim of present analysis was to assess cost-effectiveness of leno-
grastim in comparison with other G-CSFs—ﬁlgrastim and pegﬁlgrastim in Polish 
settings (threshold is about 100,095 PLN). METHODS: Analysis covered time horizon 
of one chemotherapy cycle. A public payer perspective was adopted for cost analysis. 
The costs included were based on Polish NHF reference costs list. Data on time to 
ANC recovery, number of days with fever, length of hospital stay and antibiotics use 
were obtained from randomized controlled trials (RCTs) identiﬁed in the conducted 
systematic review. These included trials on prophylactic G-CSF use as well as trials in 
which only patients with neutropenia were included. Equations describing costs and 
QALY according to neutropenia and fever length, hospital stay and antibiotic use were 
established. RESULTS: Estimated QALY difference between lenograstim and ﬁlgras-
tim is 0.0041 (CI95%[0.0007; 0.0079]), compared to pegﬁlgrastim is 0.0039 
(CI95%[0.0004; 0.0077]). Total costs difference between lenograstim and ﬁlgrastim is 
−2,069 PLN (CI95%[−5,385; −1,039]) and compared to pegﬁlgrastim is 266 PLN 
(CI95%[−3,233; 3,633]). The ICER in comparison with pegﬁlgrastim is 68,424 PLN. 
Probability of lenograstim being cost-effective over ﬁlgrastim is 91.54% and over 
pegﬁlgrastim is 51.41%. Taking into account only trials where G-CSFs were used in 
neutropenia prophylaxis estimated QALY difference between lenograstim and ﬁlgras-
tim is 0.0049 (CI95%[0.0013; 0.0088]), compared to pegﬁlgrastim is 0.0047 
(CI95%[0.0011; 0.0086]). Total costs difference between lenograstim and ﬁlgrastim is 
−2,724 PLN (CI95%[−6,139; −475]) and compared to pegﬁlgrastim is −434 PLN 
(CI95%[−4,025; 2,996]). Probability of lenograstim being cost-effective over ﬁlgrastim 
is 96.12% and over pegﬁlgrastim is 66.82%. CONCLUSIONS: Lenograstim is domi-
nant over ﬁlgrastim and cost-effective in comparison with pegﬁlgrastim. Acknowledge-
ments: This analysis was supported by Sanoﬁ-Aventis.
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COST EFFECTIVENESS ANALYSIS OF A CLINICAL PATHWAY FOR THE 
SURVEILLANCE OF HEPATOCARCINOMA IN COLOMBIA
Romero M, Arango C, Albanes J
Fundacion Salutia, bogota, Colombia
OBJECTIVES: The objetive of this paper is an analysis of cost effectiveness of a 
proposed clinical pathway for the surveillance of hepatocellular carcinoma in Colom-
bia compared to conventional management METHODS: Economic evaluation is 
performed by designing a Markov model to simulate two cohorts, one under a surveil-
lance program through the combined use of alpha-fetoprotein and ultrasound every 
6 months and another with the current monitoring scheme with a time horizon of 30 
years and age of onset of 30 years, a rate adjustment of 3% the initial cohort of 100 
patients RESULTS: The cost in the surveillance group is US $ 1,495.548 and 
unguarded arm is U.S. $ 798,714. With the surveillance program presents 21 deaths 
caused by the disease compared with 35 deaths without monitoring program, with 
688 years of life gained and an ICER of US$ 670. As demonstrated in other studies, 
the performing monitoring for HCC reduces mortality in the population at risk. The 
clinical pathway implementation of surveillance for HCC in people with liver cirrhosis 
and HBV and HCV infection is very cost effective compared with doing nothing from 
the perspective of third-party payer in Colombia. The results maintain the cost-
effectiveness in the sensitivity analysis without major changes. CONCLUSIONS: The 
implementation of a monitoring method with alpha-fetoprotein and ultrasound every 
two years is cost effective. We recommend the implementation of clinical pathway 
assessed for its cost effectiveness in the light of life years gained as outcome.
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BORTEZOMIB IS COST-EFFECTIVE FOR FIRST-LINE TREATMENT OF 
MULTIPLE MYELOMA IN SWEDEN
Rickert JB1, Hornberger J2, Liwing J3, Aschan J3, Gjönnes L4, Dhawan R5
1Cedar Associates LLC, Menlo Park, CA, USA, 2Cedar Associates LLC and Stanford 
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OBJECTIVES: To estimate the incremental cost-effectiveness of bortezomib plus mel-
phalan and prednisone (VMP) compared with melphalan, prednisone and thalidomide 
(MPT) and melphalan plus prednisone (MP) for the treatment of ﬁrst-line multiple 
myeloma in Sweden. METHODS: We constructed a decision-theoretic model, using 
Microsoft® Excel 2007 to compare the VMP, MP and MPT regimens. Treatment 
effects of VMP and MP on progression-free survival and overall survival (OS) were 
obtained from the VISTA trial. Effects of MPT vs. MP were obtained from published 
reports of ﬁve randomized trials. Costs include drug and administration costs, adverse 
events, treatment of relapses, and end-of-life costs. Utility estimates are derived from 
the literature. A mixed treatment comparison meta-analysis indirectly compares VMP 
vs. MPT. The analytic framework is based on ‘partitioned survival analysis’ that 
allows survival data to be decomposed into three states: 1) alive before disease progres-
sion; 2) alive after progression; and 3) dead. The model estimates mean OS, quality-
adjusted life-years (QALYs), costs and cost per QALY over a 30-year time horizon, 
and performs both 1-way and probabilistic sensitivity analyses. RESULTS: VMP’s 
mean OS is 61 months compared to 42.7 and 50.2 months for MP and MPT, respec-
tively. Mean lifetime direct medical costs per patient are approximately SEK 1,193,000, 
604,000 and 920,000 for VMP, MP and MPT, respectively. Mean incremental cost 
per QALY of VMP compared to MP is SEK 676,415; 90 percent C.I. (335,578, 
710,135) and SEK 576,823; 90 percent C.I. (0, 1,444,278) compared to MPT. The 
two most inﬂuential variables in our model are 1) VMP to MP hazard ratio; and 2) 
utility after progression. CONCLUSIONS: VMP and MPT are projected to prolong 
survival relative to MP. Having ICERs less than SEK 700,000, we believe that from 
a Swedish perspective, VMP is cost-effective compared to both MP and MPT.
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VALIDATION OF HEALTH OUTCOMES RESEARCH OF CANCER
Choi S
Health Outcomes Focus, Goleta, CA, USA
OBJECTIVES: Validation of health outcomes research of cancer becomes critical for 
the quality assessment of outcomes research. In Principles of Good Practice for Deci-
sion Analytic Modeling published by ISPOR Task Force ISPOR Task Force in 2003, 
validation was suggested: internal validation, between-model validation, and external 
& predictive validation. Also, Health Technology Assessment NHS R&D HTA Pro-
gramme published Review of guidelines for good practice in decision-analytic model-
ling in health technology assessment in 2004, suggesting a checklist of Dimension of 
quality: Structure, Data, and Consistency (internal and external). The objective of this 
research is to review and summarize validation activities in cancer outcomes researches 
published between 1998 and 2009. Secondary objective is to identify any changes in 
validation activities post regulatory guidelines. METHODS: The relevant articles are 
Abstracts A41
searched by using PubMed.gov with key words of Validation Health Economics 
Cancer. Frequencies are tabulated by validation criterion and publication year. Statisti-
cal methods employed for testing each validation criteria are summarized. RESULTS: 
Sixty-seven articles are found. 31 articles reveal validation effort. Criteria frequently 
tested for validation are external validity, internal validity, face validity, criterion 
validity, content validity, predictive, reliability, responsiveness, sensitivity. Sixty-eight 
percent of articles were published since 2003 and 89% since 2000. For testing validity 
of research model, correlation, regression, mean are statistics employed frequently. 
For testing validity of data, sensitivity & speciﬁcity, and positive predictive value are 
statistics used. CONCLUSIONS: Validation effort may have increased since 2003 
when guidelines from regulatory agencies have been published. But most articles’ vali-
dations were partially done. Few articles followed the guidelines to the full extent. In 
contrast to validation of quality of life instruments, validation of health economics 
outcomes models lacks theoretical foundation. It is recommended to follow guidelines 
to enhance credibility of the health outcomes research.
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VALUATION OF CLINICO-ECONOMIC EFFECTIVNESS OF THEATMENT 
OF CHILDREN WITH THE NON-HODGKIN LYMPHOMAS (NHLS) 
ACCORDING TO THE NHL-BFM-95 PROTOCOL
Dunaev SM
Izhevsk state medical academy, Izhevsk, Udmurt republic, Russia
OBJECTIVES: to estimate medical, social and economic effectiveness of treatment of 
children with the Non-Hodgkin lymphomas (NHLs) according to the NHL-BFM-95 
protocol. METHODS: The study included 62 children with NHL, 50 of them with 
B-cell lymphomas, and 12 with T-cell lymphomas. All children received treatment 
according to the NHL-BFM-95 protocol. Eighteen children, 12 boys and 6 girls, 
entered a study group aimed at estimating gained years of quality-adjusted life years. 
As of January 1st, 2010 the follow-up period comprised 13 years. Survival rates were 
estimated using the Kaplan–Meier method. RESULTS: A 5-year event-free survival of 
patients treated according to the NHL-BFM-95 protocol for patients with B-cell and 
T-cell lymphomas was 0,81 ± 0,08 and 0,54 ± 0,14 respectively. Chemotherapy 
complications appear to be the main reason for mortality during program treatment 
which is a rate of controlled mortality correlating with the quality of the accompany-
ing treatment. The assumed number of quality-adjusted life years were estimated for 
each of the patients considering the known disease outcome. A total of 657 years of 
quality-adjusted life years were saved for 18 patients with NHL treated according to 
the NHL-BFM-95 protocol; therefore the average rate is 36,5 years. This rate could 
be used for cost-effectiveness analysis of treatment as a proof of expensive treatment 
advisability for society from cost perspective. In 2009, the Republic children’s clinical 
hospital (Izhevsk) conducted a survey on clinico-economic cost of treatment of chil-
dren with NHL according to the NHL-BFM-95 protocol. The cost of one patient 
illness appeared to be US$29,550. The method of cost-effectiveness analysis on this 
medical technology with the calculation of saved years of employability and GDP 
produced during this time (US$1356 estimated) demonstrates its social effectiveness. 
CONCLUSIONS: The performed clinoco-economic analysis proves medical, social 
and economic effectiveness of treatment of children with NHL according to the NHL-
BFM-95 protocol.
PCN93
COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE COMPARED TO 
ALEMTUZUMAB AND CHLORAMBUCIL FOR CHRONIC LYMPHOCYTIC 
LEUKEMIA IN A TREATMENT-NAIVE POPULATION
Malin J1, Kongnakorn T2, Sterchele J3, Salvador C3, Getsios D4, Mwamburi M2
1David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, 2United Biosource 
Corporation, Lexington, MA, USA, 3Cephalon, Frazer, PA, USA, 4United BioSource 
Corporation, Halifax, NS, Canada
OBJECTIVES: Bendamustine and alemtuzumab are approved for treatment of chronic 
lymphocytic leukemia (CLL) in the US, and both are more expensive than chloram-
bucil. This analysis evaluated the cost-effectiveness of bendamustine (100 mg/m2/day 
intravenously, for 6 28-day cycles) vs. alemtuzumab (30 mg intravenously, for 12 
weeks) vs. chlorambucil (0.8 mg/kg/day orally, for 12 cycles) in ﬁrst-line treatment of 
CLL in the US. METHODS: The model was a discrete event simulation from a payer 
perspective, discounted at 3% annually with a lifetime horizon. Simulated patients 
were assigned baseline characteristics, treatment response, risk of adverse events, and 
infections based on data from 2 pivotal trials (Knauf et al, 2007; Knauf et al, 2009: 
bendamustine; Hillmen et al 2007: alemtuzumab) and supplemented by literature. 
Progression-free survival (PFS) and survival were predicted using survival functions 
derived from the bendamustine trial data. Resource use, costs (2009 US$), and utilities 
were from US databases and literature. RESULTS: The median PFS for bendamustine, 
alemtuzumab, and chlorambucil were 24, 15, and 11 months, respectively, and the 
total costs/patient were $75,243, $113,350, and $38,700, respectively. The incremen-
tal life years (LY) and quality-adjusted life years (QALYs) for bendamustine vs. 
chlorambucil were 0.89 and 0.72, respectively, resulting in incremental cost-effective-
ness ratio (ICER) of $50,763/QALY. Bendamustine was dominant over alemtuzumab, 
i.e., the incremental LYs and QALYs for bendamustine were 0.73 and 0.57, respec-
tively, at lower costs. Sensitivity analyses over a wide range of parameters indicated 
that bendamustine was dominant over alemtuzumab in all scenarios. The ICERs for 
bendamustine vs. chlorambucil ranged between $44,819 and $62,624/QALY. CON-
CLUSIONS: Treatment of CLL with bendamustine costs less and provides better 
health outcomes compared to alemtuzumab. Although bendamustine led to higher 
costs vs. chlorambucil, bendamustine was associated with an additional year of PFS, 
and the estimated ICER was within the acceptable, threshold commonly used in the 
US of $50,000–$100,000/QALY.
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COST-MINIMIZATION ANALYSIS OF BIOPSY-BASED RISK 
STRATIFICATION TOOLS IN INTERMEDIATE-RISK PROSTATE CANCER 
PATIENTS
Zubek VB, Khan F
Aureon Laboratories, Inc., Yonkers, NY, USA
OBJECTIVES: Prostate Cancer (PCa) disease management for intermediate-risk 
patients is challenging due to the uncertainty in risk at the time of biopsy. Novel 
prognostic tools that better estimate the risk of disease progression post-biopsy may 
save costs and improve quality of life by directing patients to more appropriate treat-
ments. We analyzed the cost of PCa management for patients stratiﬁed as intermediate-
risk by American Urological Association (AUA) guidelines. Management strategies 
were modeled according to standard care and following a new prognostic tool, Pros-
tate Px®+. The new test employs morphologic and biomarker features, in addition to 
the AUA clinical-pathologic ones, to predict PCa disease progression at biopsy. 
METHODS: A cost-minimization analysis was performed on a multi-institution 
cohort of 399 AUA intermediate-risk patients. Px+ reclassiﬁed 69% of patients as 
low-risk and 31% as high-risk. A decision analysis model was developed, accounting 
for ﬁve primary treatments (radical prostatectomy (RP), radiation therapy, primary 
hormonal therapy, brachytherapy and active surveillance) plus secondary treatments. 
Standard management for AUA intermediate-risk was compared with management 
post Px+ reclassiﬁcation. Patients reclassiﬁed as low-risk were assumed to follow low-
risk treatment distributions and disease progression; those reclassiﬁed as high-risk 
were assumed to follow high-risk treatment distributions and disease progression. The 
model was informed with costs and probabilities from the literature and analyzed 
from Medicare’s perspective with a 10 year time horizon. RESULTS: The expected 
cost per patient of standard management was $30,287 and $27,987 for Px+ (including 
the $2,968 list price), resulting in an expected cost savings of $2,300. One-way sen-
sitivity analysis conﬁrmed that modeled management post Px+ saves costs for all 
variables except for certain values of recurrence probabilities post RP in low-risk and 
intermediate-risk patients. CONCLUSIONS: Novel personalized risk assessment tools 
such as Px+ improve PCa risk stratiﬁcation, impacting disease management and 
potentially saving costs over current standards.
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COST-EFFECTIVENESS OF SEROTONIN-TYPE 3 RECEPTOR 
ANTAGONISTS FOR CHEMOTHERAPY-INDUCED EMESIS IN NON 
SMALL CELL LUNG CANCER PATIENTS RECEIVING CISPLATIN-BASED 
CHEMOTHERAPY
Colayco DC, Hay J
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: To determine, from the societal perspective, the relative cost-effective-
ness of four serotonin-type-3 receptor antagonists (5HT3-RA’s), palonosetron, ondan-
setron, granisetron, and dolasteron, for chemotherapy-induced nausea and vomiting 
(CINV) in patients with non-small cell lung cancer (NSCLC) receiving cisplatin-based 
chemotherapy. METHODS: A Markov model simulating monthly cycles was used to 
estimate lifetime costs and QALY’s gained by each of the interventions. Costs and 
utilities were discounted by 3% annually. Transition probabilities were estimated 
using clinical trial results. The study population included a hypothetical cohort with 
advanced NSCLC receiving cisplatin-based chemotherapy. In accordance with 
National Comprehensive Cancer Network guidelines, ﬁrst-line therapy for CINV 
included a 5-HT3 RA. Prochlorperazine was used for breakthrough episodes. Direct 
costs (2009 US$) included medication costs, adverse events, health care professional 
fees, hospitalizations, laboratory fees, and cancer progression costs. Indirect costs 
included the opportunity cost of medical visits. Average life expectancies were calcu-
lated from clinical trial results, adjusting for population-based life expectancies. Life 
years were weighted using utility scores elicited from the general public via a standard 
gamble technique. RESULTS: Assuming a societal cost-effectiveness threshold of 
$150,000/QALY, ondansetron and granisetron were cost-effective relative to no treat-
ment, at $103,759/QALY and $128,426/QALY, respectively. The incremental cost-
effectiveness ratio (ICER) between ondansteron and granisteron was $310,249/QALY. 
Dolasetron was dominated by ondansetron and granisetron. Palonosetron was not 
cost-effective at $799,696/QALY. In the threshold analysis, granisetron would need 
to cost $13.70/month to be cost-effective relative to ondansetron. The model was 
sensitive to changes in utility values and transition probabilities, resulting in a greater 
than 50% change in the estimated ICER. In addition, a 50–100% increase in chemo-
therapy efﬁcacy resulted in a 40–70% change in the ICER. CONCLUSIONS: For US 
patients with NSCLC on cisplatin-based chemotherapy, ondansetron is the most cost 
effective antiemetic. Generic granisetron is cost-effective relative to no antiemetics and 
at $13.70/month or less, would be cost-effective relative to ondansetron.
